Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device

Biocept expands intellectual property position to 32 issued patents globally for its highly sensitive methods for detecting cancer biomarkers in blood and other specimen types

SAN DIEGO, March 18, 2019 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Japanese Patent No. 6463668 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers a microchannel device and antibodies for the capture of rare cells of interest, including CTCs that are shed into the blood stream by solid tumors. Biocept believes the newly granted patent has claims that encompass any biological sample type of interest, and is the 32nd patent issued to Biocept that is core to its liquid biopsy technology platforms.

“The granting of this patent further expands internationally Biocept’s platform for capturing and analyzing rare cells from biological fluids, such as blood, bone marrow, cerebral spinal fluid (CSF), and tissue, to assess the status of patients with cancer,” said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept.  “This technology interfaces well with Biocept’s other patented liquid biopsy technologies, including the Company’s blood collection tube, and ctDNA analysis platform for providing information to aid physicians in the treatment of their patients with cancer.”

The technology covered by this issued patent combines Biocept’s patented microchannel platform together with antibodies to enable the capture of rare cells of interest. These technologies combine to enable the capture of cells that are present in very low numbers from blood and other biological fluids.

Michael Nall, Biocept’s President and CEO, added, “Obtaining this new patent provides additional intellectual property protection for the unique and novel features of our Target Selector™ platform, featuring our microchannel and antibody capture technologies for CTCs and other rare cells of interest. We believe that additional global intellectual property expands the opportunity for Biocept to generate revenue in territories outside the U.S.”

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the utility of our intellectual property protections, and our ability to expand opportunities to generate sales in territories outside the U.S., such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at http://www.sec.gov.

Investor Contact:
LHA
Jody Cain
Jcain@lhai.com 
310-691-7100                                                                                                                    

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-japan-for-the-capture-of-rare-cells-including-ctcs-from-any-biological-sample-of-interest-with-a-microchannel-device-300813516.html

SOURCE Biocept, Inc.

Click to view original post

Advertise With Us